Drug Profile
Research programme: fibrotic disease therapeutics - Bristol-Myers Squibb/California Institute for Biomedical Research
Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator California Institute for Biomedical Research
- Developer Bristol-Myers Squibb; California Institute for Biomedical Research
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 24 Jul 2023 NDR Batch #29- NDR Kept as it is. phase II drug is disclosed for pulmonary fibrosis as per pipeline July 2023
- 28 Feb 2019 No recent reports of development identified for preclinical development in Fibrosis in USA
- 05 Jan 2015 Preclinical trials in Fibrosis in USA (unspecified route)